65,437 trials
Smoking Cessation
Primary: Percentage of Participants With 7-day Point Prevalence of Smoking Cessation at Week 4 — 58.79 percentage of participants
Epilepsy
Primary: The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase — 0.375 proportion of subjects
Schizophrenia
Primary: Mean Change From Baseline to Last Observation After Baseline in Composite Score on the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)…
Thromboembolism · Arthroplasty, Replacement, Hip
Primary: Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 53; 75; 60 Participants — p=0.5648
Bipolar I Depression
Primary: The Mean Change From Baseline to Endpoint (Week 8 or Last Observation After Baseline) in the 30 Item Inventory of Depressive Symptomatology Clinician Rated (IDS C30)…
Cystic Fibrosis · Lung Infection · Pseudomonas Aeruginosa
Primary: Change From Baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28 — 1.41; 3.22 Units on a scale — p=0.433
Nicotine Dependence
Primary: Time to Relapse to Smoking in the 5-week Relapse Prevention Phase. — 14.5; 12.4 days
Atrial Fibrillation
Primary: Frequency (Occurrence Rates) of Major Bleeding Event — 0; 1.7; 3.2 Percentage of patients
Generalized Anxiety Disorder
Primary: Change From Baseline in the Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score at Endpoint — 12.76; 13.56; -6.38; -5.29 Units on a scale — p=0.006
Diabetes Mellitus, Type II
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 24 — -0.67; -0.02 Percent — p=<0.001
Venous Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 61; 69 Participants — p=< 0.0001
Diabetes Mellitus, Type 2
Primary: Change From Baseline in A1C at Week 24 — -0.45; 0.28 Percent — p=<0.001
Subarachnoid Hemorrhage
Primary: Cerebral Artery Vasospasm — 16; 7 Participants
Healthy
Primary: Cmax for Norethindrone(Maximum Observed Concentration of Drug Substance in Plasma) — 10.08; 9.90 ng/mL
Arthroplasty, Replacement, Knee · Thromboembolism
Primary: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 188; 219; 163 Participants — p=0.0234